Verici Dx (Verici Dx) Liabilities-to-Assets : 0.29 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Verici Dx's Total Liabilities for the quarter that ended in Jun. 2023 was $2.67 Mil. Verici Dx's Total Assets for the quarter that ended in Jun. 2023 was $9.35 Mil. Therefore, Verici Dx's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2023 was 0.29.

Verici Dx Liabilities-to-Assets Historical Data

The historical data trend for Verici Dx's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Liabilities-to-Assets Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Liabilities-to-Assets

0.03

0.13

0.20

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
Liabilities-to-Assets	0.03	0.13	0.10	0.20	0.29

Competitive Comparison of Verici Dx's Liabilities-to-Assets

For the Diagnostics & Research subindustry, Verici Dx's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verici Dx's Liabilities-to-Assets Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Verici Dx's Liabilities-to-Assets falls into.

Verici Dx Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Verici Dx's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Liabilities-to-Assets (A: Dec. 2022 )	=	Total Liabilities	/	Total Assets
	=	2.796	/	14.305
	=	0.20

Verici Dx's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2023 is calculated as

Liabilities-to-Assets (Q: Jun. 2023 )	=	Total Liabilities	/	Total Assets
	=	2.665	/	9.353
	=	0.28

Verici Dx (OTCPK:VRCDF) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Verici Dx Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Verici Dx's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (Verici Dx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Liabilities-to-Assets

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines